Investigating the valuable PAD resources from three different major cohorts worldwide, we re-examined all TACI variants in a patient-based setting and identified significant independent modifying factors influencing the penetrance of the antibody deficiency in at least 50% of the cohort (Fig. 3). The gene discussed is TNFRSF13B; the disease is agammaglobulinemia.